Drug maker GW Pharmaceuticals PLC (GWP.LN) Tuesday said it has entered a strategic alliance with a U.K. university to further its research into the use of cannabis to treat diabetes and other metabolic diseases.

GW, which has filed its cannabis-derived drug Sativex for regulatory approval following a successful phase three trial in March, said it entered an alliance with Professor Mike Cawthorne and the Clore Laboratory at the University of Buckingham, England.

The alliance will research cannabis-derived compounds, or cannabinoids, in the field of diabetes and metabolic disease. Prof. Cawthorne is a former director of diabetes research at Smithkline Beecham, a forerunner of GlaxoSmithKline PLC (GSK.LN), where he and his team discovered the best-selling diabetes drug Avandia.

The alliance will provide GW with dedicated facilities to undertake preclinical work on cannabinoids and exclusive access to therapies under evaluation at the Clore lab, the company said.

Company Web site: www.gwpharm.com

-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.